Endocyte, Inc. (ECYT) Gains Following Clinical Update, Q2 Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Chardan Capital Affirms Endocyte (ECYT) at Buy Following Q2 Results, Operational Update
July 30, 2014 2:49 PM EDTChardan Capital affirms Endocyte (Nasdaq: ECYT) at Buy with a price target of $15 following Q2 results and updated information of EC1456.
Analyst Ling Wang commented, ECYT reported 2Q14 EPS of $0.54, vs. consensus... More
